Newsletter Tool

PM Tracker

Today’s Big News

Nov 4, 2024

Election spotlight: As Harris and Trump face off, what's at stake for pharma?

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist

Boston Scientific bolsters pulsed field ablation business with Cortex buy

Viking's oral obesity med sails ahead, posting 6.8% weight loss for highest dose in phase 1

Nektar pads wallet with $90M manufacturing plant sale to Ampersand

In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals

Featured

Election spotlight: As Harris and Trump face off, what's at stake for pharma?

By Zoey Becker

Americans are already casting votes for the next president, but questions around drug pricing and the pharma industry will likely loom after the winner is decided.

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist

By James Waldron

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Boston Scientific bolsters pulsed field ablation business with Cortex buy

By Conor Hale

Cortex’s FDA-cleared OptiMap system includes a basket-shaped catheter designed to fill the heart’s chambers with 64 electrodes.

Viking's oral obesity med sails ahead, posting 6.8% weight loss for highest dose in phase 1

By James Waldron

Viking Therapeutics is rowing its longboat toward the front of the oral obesity therapy race, posting detailed data from its phase 1 trial that suggest its dual agonist of GLP-1 and GIP can hold its own in a crowded field.

Nektar pads wallet with $90M manufacturing plant sale to Ampersand

By Fraiser Kansteiner

Nektar is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity firm Ampersand for a total value of $90 million. The deal is expected to extend Nektar's cash runway into 2026 and help the company hone its development of novel immunology drugs.

In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals

By Angus Liu

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against competitors.

Swiss biotech inks reverse merger with GI-focused Renexxion

By Gabrielle Masson

Swiss biotech Relief Therapeutics is slated to enter a reverse merger with private U.S. biotech Renexxion and forge ahead with the latter’s gastrointestinal pipeline.

AstraZeneca backs American Lung Association campaign to improve lives of COPD patients

By Andrea Park

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD.

Spanish gene editing biotech licenses DNA-cutting enzymes from Caszyme for up to $43M

By Darren Incorvaia

Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the company announced on Nov. 4.

BioNTech reports surprising COVID vaccine sales in Q3 but tempers expectations for annual sales

By Kevin Dunleavy

BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter. Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2.5 billion to €3.1 billion.

BigHat unveils next-gen ADC designed with Lonza’s Synaffix as lead program

By Gabrielle Masson

BigHat Biosciences is adding Synaffix’s antibody-drug conjugate (ADC) tech to its wardrobe, pairing the science with its antibody design platform to tailor a next-gen ADC pipeline.

Fierce podcasts

Don’t miss an episode

Drug pricing and the 2024 presidential election

This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy.

The pulse of the medtech industry

Closing the menopause care gap

Resources

Whitepaper

7 “Make or Break” Factors for Emerging Biopharma Companies

This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Intensified Biomanufacturing

Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game!

Sponsored by: Syngene International Ltd.

Whitepaper

Is That Heart Attack Really an Adverse Event?

Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results.

Planning for success in cell-based manufacturing

Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes.

Presented by: Thermo Fisher Scientific